William Guyer

CDO William Guyer sells 20,000 CORT shares at $70.60 under pre-arranged 10b5-1 plan; retains 150,000 stock options.

William Guyer, Chief Development Officer of Corcept Therapeutics, sold 20,000 shares at $70.60 on 2026-06-02 as part of a scheduled 10b5-1 trading plan adopted on 2024-11-27. The trade reduced his direct shareholding from 23,985 to 3,985 shares while leaving 150,000 stock options intact. The stock has appreciated 40.8% over the prior 30 days and 113.4% over 90 days, and currently trades at $72.65—near its 52-week range of $28.66–$91.00 and only 20.2% below the recent high. Across his same-ticker history at CORT, Guyer's five prior sales show a volatile pattern: gains in the 30 days following two May 2026 and November 2025 sales, but losses between -55.1% and -57.0% over 90 days after both December 2025 sales. The company is unprofitable (net income $-31.8M against revenue of $164.9M) with a elevated P/E of 165.11. Because this sale is pre-arranged and scheduled rather than discretionary, the filing provides limited signal about Guyer's current conviction; investors should note the structured execution and monitor whether the company's profitability trajectory aligns with its valuation.

Corcept CDO exercises options and immediately sells 20k shares; stock down sharply from highs as company posts recent quarterly loss.

William Guyer, Chief Development Officer, exercised stock options and sold the full grant on the same day—a pattern that mirrors his trading history of selling Corcept stock but breaks from his pure-sell track record with an accompanying option exercise. The stock has retreated notably from its recent highs, even as the company reports growing annual revenue and remains profitable on a full-year basis; however, the most recent quarter showed a net loss, signaling operational challenges. Guyer's prior sales in this stock produced mixed timing outcomes: while three trades saw subsequent share price declines (well-timed exits), two others saw the stock rise after the sale, indicating his previous exits from Corcept have not consistently preceded major declines. This current exercise-and-sell occurs in a stock trading well below its peak and follows a period of near-term strength, making it a standard liquidity event rather than a signal of deep insider concern about the company's direction.

CDO Guyer sold 20,000 shares (94.2% of holdings) at $80.08 avg; stock +12.8% in 30d, +20.6% in 90d.

Guyer William, Chief Development Officer, executed 2 separate sales totaling 20,000 shares for $1,601,526.06 on 2025-12-02, reducing his position from 21,235 shares to 1,235 shares (a 94.2% reduction). The blended average sale price was $80.08, compared to the current price of $83.67, meaning the sales were executed 3.6% below current levels. At the same-ticker level, Guyer's recent activity shows 3 sells on 2025-11-05 (outcomes not yet measurable) and 1 sell on 2025-10-07 that has declined 18.8% in the 30-day window; his prior sell on 2025-09-02 saw the stock rise 21.4% in 30 days and 13.3% in 90 days—marking poor timing. His cross-ticker track record shows an average 90-day return of +6.1% after sells, with a 42.86% well-timed rate, suggesting his prior sales have generally been poorly timed (stock rose after he sold). The heavy reduction in his equity stake during a period of strong 30-day and 90-day price momentum warrants attention, particularly given the company's robust revenue growth of +39.9% year-over-year and a price that remains 26.8% below its 52-week high.

CDO Guyer sells 20,000 shares (79.1% of holdings) at $75.36 avg; stock now -16.6% in 30 days, -35.5% from 52-week high

William Guyer, Chief Development Officer, executed 3 separate sales totaling 20,000 shares for $1,507,121.70 on 2025-11-05, reducing his holdings by -79.1% from 25,287 shares to 5,287 shares. He sold at a blended average price of $75.36, but the stock has declined significantly since: -16.6% in the past 30 days and -35.5% from the 52-week high of $114.22, now trading at $73.72. Across his same-ticker history at CORT, Guyer's 5 prior sales show mixed timing outcomes, with only 1 of 2 measurable 90-day periods producing a well-timed result; his cross-ticker track record of 8 prior sells reflects a 60.00% well-timed rate and +3.3% average 90-day return, suggesting modest forward predictive power. The scale of this reduction—nearly eliminating his holdings—combined with subsequent sharp price weakness, warrants investor attention to whether corporate developments or market conditions prompted this concentrated exit.

CDO William Guyer sells 20,000 CORT shares at $89.94; stake reduced 79.1% to 5,287 shares

William Guyer, CDO of Corcept Therapeutics, sold 20,000 shares (79.1% of his pre-transaction holdings) on 2025-10-07 at $89.94, reducing his stake from 25,287 to 5,287 shares. The magnitude of this reduction—nearly four-fifths of holdings—is notable for a chief development officer, a role typically aligned with company execution strategy. Stock price has declined 22.6% from its 52-week high of $114.22, though it is up 23.2% over the past 30 days and up 22.9% over 90 days. At CORT specifically, Guyer's prior two measurable 90-day outcomes showed +21.4% and +20.6% gains post-sale, while his cross-ticker track record shows a 75.00% well-timed sell rate across 7 prior sales. The company's fundamentals remain solid (revenue $194.4M, net income $35.1M, annual growth +39.9%), but his near-complete exit from a material stake warrants attention to whether operational or portfolio considerations are driving the divestiture.

CDO Guyer sells 20,000 CORT shares (78.5% of holdings) for $1.4M on 2025-09-02 at blended avg $70.49

William Guyer, Chief Development Officer, executed two separate sales totaling 20,000 shares for $1,409,848.26, reducing his post-transaction holdings from 25,487 to 5,487 shares (a 78.5% reduction). The sales occurred at prices near the current market level ($70.49 blended average vs. $69.37 current price), not at an elevated peak; notably, the stock is currently -39.3% from its 52-week high of $114.22, suggesting the insider sold well above recent market lows. His prior trade history at CORT shows mixed timing outcomes: one of five prior trades was well-timed at the 90-day mark, with a most recent sale on 2025-08-10 (outcome not yet measurable) and earlier sales in June showing slight headwinds (-0.5% and -1.0% at 30 days). The company's fundamentals remain solid (revenue $194.4M, net income $35.1M, annual growth +39.9%), but the P/E of 54.62 reflects a premium valuation. The large reduction in personal holdings warrants monitoring to assess whether this signals a material shift in executive positioning or a one-time liquidity event.

Chief Development Officer William Guyer sold 35,007 shares (86.4% of holdings) of CORT at $71.77 for $2.5M on 2025-08-08.

Guyer executed a substantial reduction in his CORT position, selling 35,007 shares and retaining only 5,487 shares post-transaction. At the transaction price of $71.77, the stock was trading 35.6% below its 52-week high of $114.22, suggesting the sale occurred during a period of relative weakness. His prior sales at CORT show mixed outcomes: three recent sells (2025-06-10 and 2025-05-16) posted small negative 30-day returns (-0.5% to -5.6%), while an earlier sell on 2025-03-04 saw positive 90-day returns (+21.4%). Across his broader cross-ticker track record, his sells have generated a 90-day well-timed rate of 0.00%, indicating those sales have historically not preceded declines. The company itself shows solid fundamentals with $194.4M in quarterly revenue and annual growth of 39.9%, though the P/E of 57.94 reflects elevated expectations.

CDO William Guyer sells 20,000 CORT shares (78.5% of holdings) for $1.4M at blended $72.42, retains only 5.5K shares.

William Guyer, Chief Development Officer, executed 2 separate sales totaling 20,000 shares for $1,448,474.57, reducing his holdings from 25,487 to 5,487 shares—a 78.5% reduction. The sales occurred at prices of $72.36 and $72.75 on 2025-06-10, blended at $72.42, above the current market price of $71.18 but well below the 52-week high of $114.22. At the same ticker (CORT), his prior 2 sales show mixed timing: a 2025-03-04 sale posted +21.4% return over 90 days (poorly timed, stock rose after), and a more recent 2025-05-16 sale whose outcome remains unmeasurable. The concentration of this liquidation—disposing of nearly four-fifths of his position in a single filing—stands out as a material reduction in executive ownership. CORT's fundamentals remain solid with revenue growth of 39.9% annually and net income of $20,547,000.00, though the company trades at a P/E of 56.49 and is down 37.7% from its 52-week high.

CORT CDO William Guyer sold 32,262 shares at $74.17 on 2025-05-16 (-85.5% of holdings); stock at -33.3% from 52-week high despite +39.9% revenue growth.

William Guyer, Chief Development Officer of Corcept Therapeutics, executed a substantial open-market sale on 2025-05-16, reducing his holdings from 37,749 shares to 5,487 shares—a reduction of 85.5%. The sale occurred at $74.17 per share when the stock was trading 33.3% below its 52-week high of $114.22, suggesting the executive did not time the exit to coincide with a market peak. Corcept's fundamentals show robust quarterly revenue of $157,214,000.00 and annualized growth of +39.9%, with a net income of $20,547,000.00 and P/E of 60.49, indicating a high-valuation growth profile. The stock has recovered +22.5% in the 30 days following the transaction and is up 3.7% over 90 days post-sale, signaling that Guyer's exit was not well-timed at the multi-month horizon—the company's stock performed positively after his sale despite earlier price weakness.

CDO William Guyer sold 20,000 shares of CORT at $59.07 for $1.2M, reducing stake by -78.5% to 5,487 shares

William Guyer, Chief Development Officer of Corcept Therapeutics, executed a substantial sale of 20,000 shares at $59.07, reducing his post-transaction holdings from 25,487 shares to 5,487 shares—a -78.5% reduction in position size. The transaction occurred at a price $3.08 above the current price of $55.99, and the stock has declined -16.3% over the past 30 days and -23.9% from its 52-week high of $73.61. Despite the company's strong fundamentals (Revenue $182.5M, Net income $47.2M, annual revenue growth +39.9%), the recent price weakness and the CDO's substantial near-complete exit warrant investor attention to whether this reflects a shift in strategic positioning or broader management confidence concerns.